These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 29283909)

  • 1. An update on the pathogenesis of cholesterol gallstone disease.
    Di Ciaula A; Wang DQ; Portincasa P
    Curr Opin Gastroenterol; 2018 Mar; 34(2):71-80. PubMed ID: 29283909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the role of the indigenous microbiota in cholesterol gallstone pathogenesis.
    Fremont-Rahl JJ; Ge Z; Umana C; Whary MT; Taylor NS; Muthupalani S; Carey MC; Fox JG; Maurer KJ
    PLoS One; 2013; 8(7):e70657. PubMed ID: 23923015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglycerides and gallstone formation.
    Smelt AH
    Clin Chim Acta; 2010 Nov; 411(21-22):1625-31. PubMed ID: 20699090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gallbladder mucin in pathophysiology of gallstones.
    LaMont JT; Smith BF; Moore JR
    Hepatology; 1984; 4(5 Suppl):51S-56S. PubMed ID: 6546237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of gallstones.
    Venneman NG; van Erpecum KJ
    Gastroenterol Clin North Am; 2010 Jun; 39(2):171-83, vii. PubMed ID: 20478481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion.
    Hu H; Shao W; Liu Q; Liu N; Wang Q; Xu J; Zhang X; Weng Z; Lu Q; Jiao L; Chen C; Sun H; Jiang Z; Zhang X; Gu A
    Nat Commun; 2022 Jan; 13(1):252. PubMed ID: 35017486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.
    Wang HH; Portincasa P; Wang DQ
    Eur J Clin Invest; 2016 Feb; 46(2):158-69. PubMed ID: 26683129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models of gallstone disease.
    Wang TY; Portincasa P; Liu M; Tso P; Wang DQ
    Curr Opin Gastroenterol; 2018 Mar; 34(2):59-70. PubMed ID: 29266008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the pathogenesis and treatment of cholesterol gallstones.
    Portincasa P; van de Meeberg P; van Erpecum KJ; Palasciano G; VanBerge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1997; 223():60-9. PubMed ID: 9200309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathobiology of cholesterol gallstone disease: from equilibrium ternary phase diagram to agents preventing cholesterol crystallization and stone formation.
    Portincasa P; Moschetta A; Calamita G; Margari A; Palasciano G
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Mar; 3(1):67-81. PubMed ID: 12570727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
    Wang DQ
    J Lipid Res; 2002 Nov; 43(11):1950-9. PubMed ID: 12401894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for
    Wang HH; Portincasa P; Liu M; Tso P; Wang DQ
    Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease.
    Lavoie B; Nausch B; Zane EA; Leonard MR; Balemba OB; Bartoo AC; Wilcox R; Nelson MT; Carey MC; Mawe GM
    Neurogastroenterol Motil; 2012 Jul; 24(7):e313-24. PubMed ID: 22621672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical and metabolic factors in gallstone pathogenesis.
    Donovan JM
    Gastroenterol Clin North Am; 1999 Mar; 28(1):75-97. PubMed ID: 10198779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From lipid secretion to cholesterol crystallization in bile. Relevance in cholesterol gallstone disease.
    Portincasa P; Moschetta A; Palasciano G
    Ann Hepatol; 2002; 1(3):121-8. PubMed ID: 15280810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary lipid composition in patients with cholesterol and pigment gallstones and gallstone-free subjects: deoxycholic acid does not contribute to formation of cholesterol gallstones.
    Gustafsson U; Sahlin S; Einarsson C
    Eur J Clin Invest; 2000 Dec; 30(12):1099-106. PubMed ID: 11122325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation.
    Wang HH; Afdhal NH; Gendler SJ; Wang DQ
    J Lipid Res; 2004 Mar; 45(3):438-47. PubMed ID: 14703511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macronutrients and insulin resistance in cholesterol gallstone disease.
    Tsai CJ; Leitzmann MF; Willett WC; Giovannucci EL
    Am J Gastroenterol; 2008 Nov; 103(11):2932-9. PubMed ID: 18853969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice.
    Wang DQ; Zhang L; Wang HH
    Biochim Biophys Acta; 2005 Mar; 1733(1):90-9. PubMed ID: 15749059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of gallstones.
    Carey MC
    Recenti Prog Med; 1992; 83(7-8):379-91. PubMed ID: 1529152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.